The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open label, single arm study to evaluate the efficacy of pembrolizumab for leukoplakia.
 
Ashleigh Porter
No Relationships to Disclose
 
Audrey J. Zeh
No Relationships to Disclose
 
Thu Ly
No Relationships to Disclose
 
Alyssa Serna
No Relationships to Disclose
 
Arturo Villanueva
No Relationships to Disclose
 
Wanxing Chai-Ho
No Relationships to Disclose
 
Diana Messadi
No Relationships to Disclose
 
St. John Maie
No Relationships to Disclose
 
Marilene Wang
No Relationships to Disclose
 
Eliot Abemayor
No Relationships to Disclose
 
Ezra E.W. Cohen
Consulting or Advisory Role - Bayer; BioNTech; Eisai; Gilead Sciences; Merck; MSD; Regeneron
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)